SWITCH INDICATIONS

NSCLC Disease Indication Button
CRC Disease Indication Button
Woman looking afar with text that reads Be KRAZATI® Konfident

Choose the #1 prescribed KRAS G12C inhibitor in NSCLC.2‡

Actor portrayal.

KRAZATI is indicated as monotherapy for the treatment of adults with KRAS G12C-mutated advanced NSCLC who have received ≥1 prior systemic therapy. This indication is approved under accelerated approval. See full INDICATION by tapping on Indications button above.

* Study Design: KRYSTAL-1 was a single-arm, open-label, phase 2, registrational cohort of 116 adult patients with KRAS G12C–mutated, locally advanced, or metastatic NSCLC who received at least 1 prior systemic therapy (112 evaluable for response). Prespecified endpoints included ORR, DOR, and safety; all efficacy results were based on BICR.1,3
† Outcomes: In KRYSTAL-1, 43% of patients achieved ORR (n=48/112; 95% CI: 34-53), 42% of patients (n=47/112) achieved a PR, and 0.9% (n=1/112) of patients achieved a CR.1,3
‡

Per IQVIA claims data as brand in class (KRAS G12C NSCLC) from 9/24-8/25.2

2L=second-line; BICR=blinded independent review; CI=confidence interval; CR=complete response; DOR=duration of response; KRAS=Kirsten rat sarcoma viral oncogene homologue; NSCLC=non-small cell lung cancer; ORR=objective response rate; PR=partial response.

EXPERT PERSPECTIVES ON KRAZATI WITH DR. MARTIN DIETRICH

Dr. Martin Dietrich offers his professional insight on KRAZATI as a second-line treatment option for adult patients with KRAS G12C–mutated locally advanced or metastatic non-small cell lung cancer (NSCLC).
Expert perspective on KRAZATI® (adagrasib) Dr. Martin Dietrich, AI video

INFORM YOUR KRAZATI KONFIDENCE*†

KRAS G12C

Explore information on the KRAS G12C mutation

lung with Kras G12C

Discover how KRAZATI is intentionally designed for KRAS G12C

2 times

600 mg twice-daily

oral dosing 

*Study Design: KRYSTAL-1 was a single-arm, open-label phase 2, registrational cohort of 116 adult patients with KRAS G12C-mutated, locally advanced, or metastatic NSCLC who received at least 1 prior systemic therapy (112 evaluable for response). Prespecified endpoints included ORR, DOR, and safety; all efficacy results were based on BICR.1,3
†Outcomes: In KRYSTAL-1, 43% of patients achieved ORR (n=48/112; 95% CI: 34-53), 42% of patients (n=47/112) achieved a PR, and 0.9% (n=1/112) of patients achieved a CR.1,3

References:

  1. KRAZATI [package insert]. Princeton, NJ: Bristol Myers Squibb Company; 2024.
  2. IQVIA national source data. Princeton, NJ: Bristol-Myers Squibb Company. October 20, 2025.
  3. Jänne PA, Riely GJ, Gadgeel SM, et al. Adagrasib in non-small-cell lung cancer harboring a KRASG12C mutation. N Engl J Med. 2022;387(2):120-131.
foot note heading

IMPORTANT SAFETY INFORMATION

WARNINGS AND PRECAUTIONS

Gastrointestinal Adverse Reactions

 

  • KRAZATI can cause severe gastrointestinal adverse reactions

  • Monitor and manage patients using supportive care, including antidiarrheals, antiemetics, or fluid replacement, as indicated. Withhold, reduce the dose, or permanently discontinue KRAZATI based on severity

QTc Interval Prolongation

 

  • KRAZATI can cause QTc interval prolongation, which can increase the risk for ventricular tachyarrhythmias (eg, torsades de pointes) or sudden death

  • Avoid concomitant use of KRAZATI with other products with a known potential to prolong the QTc interval. Avoid use of KRAZATI in patients with congenital long QT syndrome and in patients with concurrent QTc prolongation

  • Monitor ECGs and electrolytes, particularly potassium and magnesium, prior to starting KRAZATI, during concomitant use, and as clinically indicated in patients with congestive heart failure, bradyarrhythmias, electrolyte abnormalities, and in patients who are unable to avoid concomitant medications that are known to prolong the QT interval. Correct electrolyte abnormalities. Withhold, reduce the dose, or permanently discontinue KRAZATI, depending on severity

Hepatotoxicity

 

  • KRAZATI can cause hepatotoxicity, which may lead to drug-induced liver injury and hepatitis

  • Monitor liver laboratory tests (AST, ALT, alkaline phosphatase, and total bilirubin) prior to the start of KRAZATI, and monthly for 3 months or as clinically indicated, with more frequent testing in patients who develop transaminase elevations. Reduce the dose, withhold, or permanently discontinue KRAZATI based on severity

Interstitial Lung Disease/Pneumonitis

 

  • KRAZATI can cause interstitial lung disease (ILD)/pneumonitis, which can be fatal

  • Monitor patients for new or worsening respiratory symptoms indicative of ILD/pneumonitis (eg, dyspnea, cough, fever) during treatment with KRAZATI. Withhold KRAZATI in patients with suspected ILD/pneumonitis and permanently discontinue KRAZATI if no other potential causes of ILD/pneumonitis are identified

ADVERSE REACTIONS

 

  • Serious adverse reactions occurred in 57% of 116 patients who received adagrasib in NSCLC patients. The most common adverse reactions in NSCLC patients (≥20%) were diarrhea, nausea, fatigue, vomiting, musculoskeletal pain, hepatotoxicity, renal impairment, dyspnea, edema, decreased appetite, cough, pneumonia, dizziness, constipation, abdominal pain, and QTc interval prolongation

DRUG INTERACTIONS

 

  • Strong CYP3A4 Inducers: Avoid concomitant use.

  • Strong CYP3A4 Inhibitors: Avoid concomitant use until adagrasib concentrations have reached steady state (after ~8 days).

  • Sensitive CYP3A4 Substrates: Avoid concomitant use with sensitive CYP3A4 substrates.

  • Sensitive CYP2C9 or CYP2D6 Substrates or P-gp Substrates: Avoid concomitant use with sensitive CYP2C9 or CYP2D6 substrates or P-gp substrates where minimal concentration changes may lead to serious adverse reactions.

  • Drugs That Prolong QT Interval: Avoid concomitant use with KRAZATI.

Please see Drug Interactions Section of the Full Prescribing Information for additional information.

USE IN SPECIFIC POPULATIONS

Females and Males of Reproductive Potential

 
  • Infertility: Based on findings from animal studies, KRAZATI may impair fertility in females and males of reproductive potential

Lactation

 
  • Advise not to breastfeed

Please see Full Prescribing Information.

 

1914-US-2500139   01/26

Bristol Myers Squibb logo

© 2026 Mirati Therapeutics, Inc., a Bristol Myers Squibb company. KRAZATI® and the related logo are registered trademarks of Mirati Therapeutics, Inc.

This website is intended for U.S. residents 18 years of age or older.

1914-US-2500138   01/26

Legal Notice     Privacy Policy     Your Privacy Choices    Site Map